Conference Call with Dr. Lal Pathlabs Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Dr. Lal Pathlabs announced Q3FY25 results Revenue increased by 10.7% from Rs 597 crore in Q3FY25 to Rs 539 crore in Q3FY24.. EBITDA increased by 9.6% from Rs 154 crore in Q3FY25 to Rs 141 crore in Q3FY24, with a margin of 25.8%. PAT increased by 19.3% from Rs 98 crore in Q3FY25 to Rs 82 crore in Q3FY24, with a margin for of 16.4%. Third Interim Dividend of Rs. 6 per share for FY25. Result PDF